Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Myriad Genetics (NASDAQ: MYGN) has released preliminary financial results for Q4 and full year 2024, along with 2025 guidance. The company expects Q4 2024 revenues between $209-211 million, representing a 6-7% increase year-over-year, and full-year 2024 revenues of $836-838 million, up 11% from 2023.
Q4 2024 is expected to show a GAAP diluted loss per share of $(0.72)-$(0.62) and adjusted EPS of $0.03-$0.04. Full-year 2024 GAAP loss per share is projected at $(1.66)-$(1.56) with adjusted EPS of $0.14-$0.15. The company anticipates Q4 GAAP net loss between $(65.7)-$(56.8) million and adjusted EBITDA of $10-11 million.
Cash and cash equivalents stood at approximately $102 million as of December 31, 2024, showing a $2 million increase from Q3 2024. Final audited results will be released during the February 2025 earnings call.
Myriad Genetics (NASDAQ: MYGN) ha pubblicato i risultati finanziari preliminari per il quarto trimestre e l'intero anno 2024, insieme alle previsioni per il 2025. L'azienda prevede che i ricavi del Q4 2024 si attesteranno tra $209-211 milioni, con un aumento del 6-7% rispetto all'anno precedente, e ricavi dell'anno intero 2024 di $836-838 milioni, in crescita dell'11% rispetto al 2023.
Si prevede che il Q4 2024 mostrerà una perdita diluita GAAP per azione compresa tra $(0.72)-$(0.62) e un EPS rettificato di $0.03-$0.04. La perdita per azione GAAP dell'intero anno 2024 è stimata tra $(1.66)-$(1.56) con un EPS rettificato di $0.14-$0.15. L'azienda prevede una perdita netta GAAP per il Q4 compresa tra $(65.7)-$(56.8) milioni e un EBITDA rettificato di $10-11 milioni.
Le disponibilità liquide e equivalenti ammontano a circa $102 milioni al 31 dicembre 2024, con un incremento di $2 milioni rispetto al Q3 2024. I risultati finali verificati saranno pubblicati durante la call sugli utili di febbraio 2025.
Myriad Genetics (NASDAQ: MYGN) ha publicado resultados financieros preliminares para el cuarto trimestre y el año completo 2024, junto con las proyecciones para 2025. La compañía espera que los ingresos del Q4 2024 se ubiquen entre $209-211 millones, lo que representa un aumento del 6-7% en comparación con el año anterior, y unos ingresos para todo el año 2024 de $836-838 millones, un incremento del 11% respecto a 2023.
Se espera que el Q4 2024 muestre una pérdida diluida GAAP por acción de $(0.72)-$(0.62) y un EPS ajustado de $0.03-$0.04. La pérdida por acción GAAP proyectada para todo el año 2024 es de $(1.66)-$(1.56), con un EPS ajustado de $0.14-$0.15. La compañía anticipa una pérdida neta GAAP para el Q4 entre $(65.7)-$(56.8) millones y un EBITDA ajustado de $10-11 millones.
El efectivo y equivalentes de efectivo se situaron en aproximadamente $102 millones al 31 de diciembre de 2024, mostrando un aumento de $2 millones desde el Q3 2024. Los resultados finales auditados se publicarán durante la llamada de ganancias de febrero de 2025.
Myriad Genetics (NASDAQ: MYGN)는 2024년 4분기 및 전체 연도에 대한 예비 재무 결과와 2025년 지침을 발표했습니다. 회사는 2024년 4분기 수익을 $209-211백만으로 예상하며, 이는 전년 대비 6-7% 증가한 수치입니다. 2024년 전체 연도 수익은 $836-838백만으로 2023년 대비 11% 증가할 것으로 보입니다.
2024년 4분기 GAAP 기준 희석 주당 손실은 $(0.72)-$(0.62)로 예상되며, 조정된 주당순이익(EPS)은 $0.03-$0.04가 될 것으로 보입니다. 2024년 전체 GAAP 주당 손실은 $(1.66)-$(1.56)으로 예상되며, 조정된 EPS는 $0.14-$0.15입니다. 회사는 4분기 GAAP 기준 순손실이 $(65.7)-$(56.8)백만 사이에 있을 것으로 예상하고, 조정된 EBITDA는 $10-11백만으로 예상하고 있습니다.
2024년 12월 31일 기준으로 현금 및 현금성 자산은 약 $102백만으로, 2024년 3분기 대비 $2백만 증가한 수치입니다. 최종 감사 결과는 2025년 2월 실적 전화회의에서 발표될 예정입니다.
Myriad Genetics (NASDAQ: MYGN) a publié des résultats financiers préliminaires pour le quatrième trimestre et l'année complète 2024, ainsi que des prévisions pour 2025. La société s'attend à ce que les revenus du Q4 2024 soient compris entre $209-211 millions, ce qui représente une augmentation de 6-7 % par rapport à l'année précédente, et des revenus pour l'année entière 2024 de $836-838 millions, en hausse de 11 % par rapport à 2023.
On s'attend à ce que le Q4 2024 montre une perte diluée GAAP par action comprise entre $(0.72)-$(0.62) et un bénéfice par action ajusté de $0.03-$0.04. La perte par action GAAP pour l'ensemble de l'année 2024 est projetée entre $(1.66)-$(1.56) avec un bénéfice par action ajusté de $0.14-$0.15. La société anticipe une perte nette GAAP pour le Q4 comprise entre $(65.7)-$(56.8) millions et un EBITDA ajusté de $10-11 millions.
Les liquidités et équivalents de liquidités s'élevaient à environ $102 millions au 31 décembre 2024, montrant une augmentation de $2 millions par rapport au Q3 2024. Les résultats finaux audités seront publiés lors de la conférence de résultats de février 2025.
Myriad Genetics (NASDAQ: MYGN) hat vorläufige Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht, zusammen mit den Prognosen für 2025. Das Unternehmen erwartet für das Q4 2024 Umsätze zwischen $209-211 Millionen, was einem Anstieg von 6-7 % im Vergleich zum Vorjahr entspricht, und für das Gesamtjahr 2024 Umsätze von $836-838 Millionen, was einer Steigerung von 11 % gegenüber 2023 entspricht.
Für das Q4 2024 wird ein GAAP-diluted Verlust pro Aktie zwischen $(0.72)-$(0.62) und ein adjusted EPS von $0.03-$0.04 erwartet. Für das gesamte Jahr 2024 wird ein GAAP-Verlust pro Aktie zwischen $(1.66)-$(1.56) mit einem adjusted EPS von $0.14-$0.15 prognostiziert. Das Unternehmen rechnet im Q4 mit einem GAAP-Nettoverlust zwischen $(65.7)-$(56.8) Millionen und einem adjusted EBITDA von $10-11 Millionen.
Die liquiden Mittel und Äquivalente beliefen sich zum 31. Dezember 2024 auf etwa $102 Millionen, was einem Anstieg von $2 Millionen im Vergleich zum Q3 2024 entspricht. Die endgültigen geprüften Ergebnisse werden während der Gewinnkonferenz im Februar 2025 veröffentlicht.
- Revenue growth of 11% year-over-year for full-year 2024
- Q4 2024 revenue growth of 6-7% year-over-year
- Cash position improved by $2 million from Q3 2024
- Positive adjusted EBITDA of $40-41 million for full year 2024
- Significant GAAP net loss of $(151)-$(142) million for full year 2024
- Q4 2024 GAAP net loss of $(65.7)-$(56.8) million
- Full year 2024 GAAP loss per share of $(1.66)-$(1.56)
- Low adjusted EPS of $0.14-$0.15 for full year 2024
Insights
The preliminary Q4 and FY2024 results showcase mixed performance. Revenue growth of
The adjusted metrics paint a slightly better picture - Q4 adjusted EPS of
Key concerns include the substantial gap between GAAP and adjusted figures, indicating significant one-time or non-operational costs impacting profitability. The modest adjusted EBITDA margins around
The diagnostic testing market context is important here. While Myriad's revenue growth appears solid, it's actually lagging behind the broader molecular diagnostics sector's growth rate of
The preliminary results timing, ahead of the JP Morgan Healthcare Conference, suggests strategic positioning to engage investors and partners. The modest growth and persistent GAAP losses might impact investor sentiment, particularly as peers are showing stronger profitability metrics. The cash position, while stable, may limit strategic flexibility for potential M&A or R&D investments needed to accelerate growth.
SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance.
Select Preliminary Fourth Quarter and Full Year 2024 Financial Results
The company expects the following:
- Fourth quarter of 2024 total revenues to be between
$209 million and$211 million , an increase of approximately6% to7% compared to fourth quarter of 2023. Full year 2024 total revenues to be between$836 million to$838 million , an increase of approximately11% compared to full year 2023. - Fourth quarter of 2024 GAAP diluted loss per share to be between
$(0.72) and$(0.62) and adjusted diluted earnings per share (EPS) to be between$0.03 and$0.04 . Full year 2024 GAAP loss per share to be between$(1.66) and$(1.56) and adjusted EPS to be between$0.14 and$0.15 . - Fourth quarter of 2024 GAAP net loss to be between
$(65.7) million and$(56.8) million and adjusted EBITDA to be between$10 million and$11 million . Full year 2024 GAAP loss to be between$(151) million and$(142) million and adjusted EBITDA to be between$40 million and$41 million . - As of December 31, 2024, cash and cash equivalents were approximately
$102 million , an increase of$2 million from the end of third quarter of 2024.
These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 15, 2025 at 3:45 p.m. PT (6:45 p.m. ET) in connection with the company’s presentation at the 43rd Annual J.P. Morgan Healthcare Conference. An archived edition of the presentation will be available later that day. Myriad Genetics plans to release its actual financial results for the fourth quarter and full year 2024 during its earnings call to be held in February 2025.
The select financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter and year-end accounting procedures and external audit by the company’s independent registered public accounting firm. As a result, these select preliminary, unaudited financial results may change in connection with the finalization of the company’s year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2024 and may not represent the actual financial results for the quarter and full year ended December 31, 2024. In addition, these select preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2024, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company's results for any future period.
2025 Full Year Financial Guidance
Myriad Genetics does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.
The company introduces the full year 2025 financial guidance in the table below*.
| (in millions, except per share amounts) | FY 2025 Guidance | FY 2025 Comments | |||
| Revenue | Reflects an increase of approximately | ||||
| Gross margin % | |||||
| Adjusted OPEX | |||||
| Adjusted EBITDA** | |||||
| Adjusted EPS*** | |||||
| * | Assumes currency rates as of January 15, 2025. | ||||
| ** | Adjusted EBITDA is defined as Net Income (loss) plus income tax expense (benefit), total other income (expense), non-cash operating expenses, such as amortization of intangible assets, depreciation, impairment of long-lived assets, and share-based compensation expense, and one-time expenses such as expenses from real estate optimization initiatives, transformation initiatives, legal settlements, and divestitures and acquisitions. | ||||
| *** | Full-year 2025 adjusted EPS is based on a 94 million share count. | ||||
These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s fourth quarter and full year 2024 preliminary revenue, loss per share and adjusted EPS and the other preliminary financial items included in the reconciliations below as well as the cash and cash equivalents as of December 31, 2024, the company’s full year 2025 financial guidance, and the company's plan to release actual financial results for the fourth quarter and full year 2024 in February 2025. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.
These risks include, but are not limited to: the risk that sales and profit margins of the company’s existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to changes in the company's financial results from the preliminary results reported in this press release resulting from the finalization of the company's financial statements for the fourth quarter and full year 2024 and the audit thereof; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests, including with respect to UNH's coverage decisions effective as of first quarter 2025; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company’s laboratory testing facilities and the transition of such facilities to the company's new laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if it all; risks related to the company’s projections or estimates about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial operating covenants under the company’s credit or lending agreements; the risk that the company may not be able maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading “Risk Factors” contained in Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2024 as updated in the company's Quarterly Reports on Form 10-Q filed with the SEC on May 8, 2024 and November 8, 2024 as well as any further updates to those risk factors filed from time to time in the company’s future filings with the SEC. Myriad Genetics is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Statement regarding use of non-GAAP financial measures
In this press release, the company’s preliminary financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. A reconciliation of the preliminary GAAP financial results to preliminary non-GAAP financial results is included in the schedules below and a description of the adjustments made to the preliminary GAAP financial measures is included at the end of the schedules.
The company encourages investors to carefully consider its preliminary results under GAAP, as well as its supplemental preliminary non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
The company does not forecast GAAP operating expenses, net income (loss) or earnings per share because it cannot predict certain elements that are included in reported GAAP results. Please see above under “2025 Full Year Financial Guidance” for a full explanation.
As set forth above, the company’s financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter and year-end accounting procedures and external audit by the company’s independent registered public accounting firm and therefore subject to change.
Reconciliation of Preliminary GAAP to Preliminary Non-GAAP Financial Measures
for the Three and Twelve Months Ended December 31, 2024
| Three Months Ended December 31, 2024 | Twelve Months Ended December 31, 2024 | ||||||||||||||
| Low(1) | High(2) | Low(1) | High(2) | ||||||||||||
| Adjusted Net Income (Loss)(3) | |||||||||||||||
| Net Loss | $ | (65.7 | ) | $ | (56.8 | ) | $ | (150.5 | ) | $ | (141.6 | ) | |||
| Acquisition - amortization of intangible assets | 10.0 | 10.0 | 41.5 | 41.5 | |||||||||||
| Goodwill and long-lived asset impairment charges | 45.0 | 41.0 | 58.8 | 54.8 | |||||||||||
| Equity compensation | 10.9 | 10.9 | 49.8 | 49.8 | |||||||||||
| Real estate optimization | 1.7 | 1.7 | 7.2 | 7.2 | |||||||||||
| Transformation initiatives | — | — | 6.6 | 6.6 | |||||||||||
| Legal charges | 0.1 | 0.1 | 0.6 | 0.6 | |||||||||||
| Other adjustments | 0.9 | 0.9 | 3.4 | 3.4 | |||||||||||
| Tax adjustments | 0.3 | (3.7 | ) | (4.9 | ) | (8.9 | ) | ||||||||
| Adjusted Net Income | $ | 3.2 | $ | 4.1 | $ | 12.5 | $ | 13.4 | |||||||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 91.1 | 91.1 | 90.6 | 90.6 | |||||||||||
| Diluted | 92.1 | 92.1 | 92.1 | 92.1 | |||||||||||
| GAAP Net Loss Per Share | |||||||||||||||
| Basic | $ | (0.72 | ) | $ | (0.62 | ) | $ | (1.66 | ) | $ | (1.56 | ) | |||
| Diluted | $ | (0.72 | ) | $ | (0.62 | ) | $ | (1.66 | ) | $ | (1.56 | ) | |||
| Adjusted Earnings Per Share | |||||||||||||||
| Basic | $ | 0.04 | $ | 0.05 | $ | 0.14 | $ | 0.15 | |||||||
| Diluted | $ | 0.03 | $ | 0.04 | $ | 0.14 | $ | 0.15 | |||||||
| (1) Represents the low end of the range of management’s expectations of 2024 fourth quarter and full year 2024 results. | |||||||||||||||
| (2) Represents the high end of the range of management’s expectations of 2024 fourth quarter and full year 2024 results. | |||||||||||||||
| (3) To determine Adjusted Earnings (Loss) Per Share, or adjusted EPS. | |||||||||||||||
| Three Months Ended December 31, 2024 | Twelve Months Ended December 31, 2024 | ||||||||||||||
| Low(1) | High(2) | Low(1) | High(2) | ||||||||||||
| Adjusted EBITDA | |||||||||||||||
| Net Loss | $ | (65.7 | ) | $ | (56.8 | ) | $ | (150.5 | ) | $ | (141.6 | ) | |||
| Acquisition - amortization of intangible assets | 10.0 | 10.0 | 41.5 | 41.5 | |||||||||||
| Depreciation expense | 4.7 | 4.7 | 17.9 | 17.9 | |||||||||||
| Goodwill and long-lived asset impairment charges | 45.0 | 41.0 | 58.8 | 54.8 | |||||||||||
| Equity compensation | 10.9 | 10.9 | 49.8 | 49.8 | |||||||||||
| Real estate optimization(3) | 1.7 | 1.7 | 7.2 | 7.2 | |||||||||||
| Transformation initiatives | — | — | 6.6 | 6.6 | |||||||||||
| Legal charges | 0.1 | 0.1 | 0.6 | 0.6 | |||||||||||
| Interest expense, net of interest income(4) | (0.1 | ) | (0.1 | ) | 0.6 | 0.6 | |||||||||
| Other adjustments | 0.2 | 0.2 | 3.8 | 3.8 | |||||||||||
| Income tax expense(5) | 3.2 | (0.8 | ) | 3.6 | (0.4 | ) | |||||||||
| Adjusted EBITDA | $ | 10.0 | $ | 10.9 | $ | 39.9 | $ | 40.8 | |||||||
| (1) Represents the low end of the range of management’s expectations of 2024 fourth quarter and full year 2024 results. | |||||||||||||||
| (2) Represents the high end of the range of management’s expectations of 2024 fourth quarter and full year 2024 results. | |||||||||||||||
| (3) Real estate optimization includes depreciation expense of | |||||||||||||||
| (4) Derived from interest expense and interest income from the Consolidated Statements of Operations. | |||||||||||||||
| (5) Derived from income tax (benefit) from the Consolidated Statement of Operations. | |||||||||||||||
Following is a description of the adjustments made to the preliminary GAAP financial measures:
- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Goodwill and long-lived asset impairment charges:
- For the three months ended December 31, 2024, consists of the impairment of acquired technology intangible assets related to our GeneSight Test.
- For the twelve months ended December 31, 2024, consists of the impairment of acquired technology intangible assets related to our GeneSight Test and the impairment of assets held for sale related to the sale of the EndoPredict business to Eurobio Scientific.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Real estate optimization – costs related to real estate initiatives. These costs include additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah, and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities, lease termination gains, net of lease termination losses, impairment charges and other abandonment costs.
- Transformation initiatives – costs related to transformation initiatives including consulting and professional fees.
- Legal charges – one-time legal expenses.
- Other adjustments – other one-time non-recurring expenses including a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, severance, and costs incurred in connection with executive personnel changes.
- Tax adjustments – tax expense (benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
What is Myriad Genetics' (MYGN) expected revenue for Q4 2024?
What is MYGN's projected full-year revenue for 2024?
What is Myriad Genetics' (MYGN) cash position as of December 31, 2024?
What is MYGN's expected adjusted EBITDA for full year 2024?
What is Myriad Genetics' (MYGN) projected GAAP loss per share for 2024?
